David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai.
A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI FOLFOXaiTM, the latest addition to the company’s extensive molecular science portfolio. MI FOLFOXai is an Artificial Intelligence (AI)-based predictor of FOLFOX chemotherapy response in metastatic colorectal cancer that showed an increase of approximately 50 percent in overall survival through two independent validation studies. Using the findings of Caris Molecular Intelligence ® tumor profiling, this AI-powered predictor is designed to gage the probability of a patient benefiting from FOLFOX in combination with bevacizumab as a first-line regimen.
Two separate data sets were used to test MI FOLFOXai and equate the increased benefit arm to the decreased benefit arm. The first study was a blinded, forward-looking review of retrospectively evaluated samples from the Phase III TRIBE2 randomized study. This analysis showed a 6.9-month increase in overall median survival. The second study included several hundred real-world case studies that showed an overall mean survival improvement of 11.8 months.